Interview with Michel Mommejat, President / Representative Director and Chief Innovation Officer @ A.D.A.M. Innovations (Genesis Healthcare – GeneLife)

Michel, can you tell us about your professional background and your current role at A.D.A.M. Innovations?

I have over two decades of international leadership experience in driving digital transformation, data strategy, and brand innovation across multiple industries. My career spans senior executive roles at global companies, where I have led large-scale digital initiatives, strategic partnerships, and growth programs in both developed and emerging markets.

I currently serve as President, Representative Director, and Chief Innovation Officer of A.D.A.M. Innovations, where I am spearheading the company’s transformation into a next-generation AI and genomics platform. In this role, I focus on integrating multi-omic data, artificial intelligence, and advanced analytics to build predictive, preventive, and personalized health solutions that can scale globally.

Your career spans five major global cities: France, Boston, London, Singapore, and Tokyo. How did these diverse cultural and business environments shape your worldview and, specifically, drive you toward a career in marketing and digital transformation?

My career journey across France, the USA, the UK, Singapore, and Japan has profoundly shaped my global perspective and strategic approach.

Born and raised in Southwest France, I developed an early passion for marketing and international culture, studying marketing in Toulouse. After graduation, I moved to Boston, where I witnessed the shift from traditional advertising to data-driven marketing and the early rise of the internet.

I began my career in CRM and data in France before moving to London, focusing on global and multi-market management. Three years later, I moved to Japan to start a digital marketing agency and spent six years at the forefront of the world’s most advanced mobile marketing market.

I then spent nine years in Singapore, leading regional digital and data transformation across Asia-Pacific, from Australia to India, Southeast Asia, and Northeast Asia.

Returning to Japan, I transitioned from marketing to innovation, combining decades of experience in digital and data with a growing passion for personal data, health, and technology. This led me to A.D.A.M. Innovations, where I now drive innovation at the intersection of genomics, AI, and multi-omic data to shape the future of personalized health.

Prior to A.D.A.M. Innovations, you held significant global executive roles. What is the most critical lesson you learned in organizational transformation or digital strategy from that time that you now successfully apply in the specialized biotech and health-tech space?

The key lesson is that technology doesn’t drive transformation, people and culture do. In previous roles, success came from aligning a clear vision with cross-functional collaboration, cultural readiness, and continuous training to upskill teams for new capabilities. At A.D.A.M. Innovations, this approach enables us to bridge genomics, AI, and multi-omic data with organizational execution, accelerating innovation in a complex regulatory and scientific environment.

As President and Chief Innovation Officer, what specific initiatives or strategic shifts have you implemented that have most significantly accelerated A.D.A.M. Innovations’ growth and defined its current market direction?

Our transformation is articulated around three core initiatives. First, we are evolving from a genetic testing and research-focused organization to an AI-driven precision health company. Second, we are applying AI and integrating diverse data sets to develop new predictive models tailored to Japanese and broader Asian populations. Finally, we are introducing new strategic and commercial services that expand access to genomic data and analytics for researchers, empower consumers with genomic insights for health prevention, and enable corporations to drive personalized product innovation and engagement. Together, these initiatives have positioned us as a frontrunner in Japan’s precision health ecosystem.

A.D.A.M. Innovations champions precision health and AI-driven solutions. How do you ensure your operational and innovation strategies are perfectly aligned with this core mission, and what key initiatives have you led to amplify this vision?

Our mission is to make a meaningful impact on people’s lives and celebrate humanity through genomic science. To achieve this, we have broken down silos between science, bioinformatics, data science, technology development, UI/UX, and marketing by integrating all teams within an open, collaborative environment at our innovation center. In addition, we have built a truly international team, with over 20% of members coming from international backgrounds, well above the average typically seen in Japan.

The company’s portfolio includes core services like GenesisGaia, GenesisPro, and GeneLife. Given your background in product planning, what was your specific role in the strategic development and market positioning of these key offerings?

Being involved across the entire genomic value chain, from testing to bioinformatics, and from clinical to consumer genomics and research, is truly exciting. It gives us the ability to continuously innovate. Our integrated team, unified under our innovation center, brings all the relevant specialties together under one roof, driving this innovation forward.

My role is to define the strategic direction of each product line and orchestrate collaboration across teams. Working across multiple countries and markets has taught me to foster effective teamwork and proactively address bottlenecks that could hinder innovation. I also closely monitor emerging technologies and solutions that can further strengthen our platform.

The key is to design a cohesive ecosystem where each product reinforces the others, enabling both scale and clear market differentiation.

The launch of GeneLink, the world’s first genetics-powered advertising platform, is a unique achievement. How did your team identify the need for this product, and what was the most critical step in its successful development and launch?

Multiple insights have driven the development of GeneLink over the years. These include our work with large corporations on R&D initiatives and supporting them in developing personalized services based on genetics. Through our consumer genomics services, we also maintain a constant pulse on consumer needs. This dual perspective allowed us to identify a clear gap between precision marketing and biological insights. Current ad-tech models rely heavily on behavioral and demographic data, which have largely reached their innovation ceiling. In this context, we saw a unique opportunity to introduce privacy-safe, biology-informed targeting. The critical step was building the right cross-functional team, combining genomics, AI, legal, and marketing expertise to design a compliant and scalable platform. GeneLink’s launch in Japan has set a global precedent for ethically aligned genetics-powered personalization.

Looking ahead, the AI in genomics market in Japan is projected to grow to USD 576.7 million by 2030. How is A.D.A.M. Innovations preparing for these trends, and are there any new products or services in development that you can share insights on?

We foresee a continued convergence of genomics with diverse biomarkers and wearable data to develop new predictive models for wellness and health prevention. This represents a truly exciting development with meaningful potential for the greater good of society.

The adoption of AI will continue to accelerate across the board, driving significant advancements in clinical testing, including next-generation liquid biopsy for early oncology detection, as well as genomic AI and data analytics for drug development and pharmacogenomics. We also expect to see gene-editing solutions increasingly applied to plants and multiple industries (e.g. wellness, nutrition, fitness, cosmectics, etc.), broadening the impact of these technologies beyond healthcare.

The Future of Precision Health in the Wellness Economy: GeneLink and A.D.A.M. Innovations sit at the intersection of healthcare, consumer personalization, and ethical AI. How do you see the company helping to define this emerging ‘wellness economy’ space, and what is its next aim in this new frontier?

We aim to redefine how genetic, health and wellness data create value, for individuals, corporations, and society. By combining genomic intelligence, AI, and privacy-first frameworks, we enable new models of personalized wellness engagement that are ethical and scalable. GeneLink is our first step, bridging consumer personalization and biology. Next, we aim to expand this ecosystem through partnerships, tokenized value models, and real-world health outcomes integration.

Based on your extensive experience, what is the single most important piece of advice you would offer to young professionals aspiring to enter the rapidly converging fields of AI, genomics, and digital health?

Stay curious, build interdisciplinary fluency, and embrace continuous learning. All these fields evolve rapidly, sitting at the intersection of science, technology, regulation, and human behavior. The most impactful professionals are those who can connect these dots, communicate clearly across domains, and remain agile as innovation accelerates.

In this rapidly evolving landscape, whether the transformation is digital, data-driven, scientific, or AI-led, staying at the forefront is essential to remain competitive and relevant.

Thank you, Michel!